RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerONCY's IND213 breast cancer study conducted by the Canadian Trials Group - found that patients with increased age, better performance status (PS), no prior paclitaxel therapy and mutations in TP53, PTEN, AKTI and KIT had longer OS, while those with PIK3CA, APC and ATM mutations had shorter OS.